Sign In
NASDAQ:ESPR
Esperion Therapeutics Stock Earnings Reports
$1.54
+0.0400 (+2.67%)
At Close: Mar 17, 2025
Esperion Therapeutics Earnings Calls
Q4 2024
Beat
-$0.100 (28.57%)
| Release date | Mar 04, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.100 |
| EPS Surprise | 28.57% |
| Revenue estimate | 51.701M |
| Revenue actual | 69.113M |
| Revenue Surprise | 33.68% |
Q3 2024
Missed
-$0.150 (-7.14%)
| Release date | Nov 07, 2024 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.150 |
| EPS Surprise | -7.14% |
| Revenue estimate | 61.555M |
| Revenue actual | 51.632M |
| Revenue Surprise | -16.12% |
Q2 2024
Beat
-$0.0500 (66.67%)
| Release date | Aug 12, 2024 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.0500 |
| EPS Surprise | 66.67% |
| Revenue estimate | 49.06M |
| Revenue actual | 73.834M |
| Revenue Surprise | 50.50% |
Q1 2024
Beat
$0.340 (580.00%)
| Release date | May 07, 2024 |
| EPS estimate | $0.0500 |
| EPS actual | $0.340 |
| EPS Surprise | 580.00% |
| Revenue estimate | 84.51M |
| Revenue actual | 137.735M |
| Revenue Surprise | 62.98% |
Last 4 Quarters for Esperion Therapeutics
Below you can see how ESPR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 07, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $2.37 |
| EPS estimate | $0.0500 |
| EPS actual | $0.340 |
| EPS surprise | 580.00% |
| Date | Price |
|---|---|
| May 01, 2024 | $2.04 |
| May 02, 2024 | $2.06 |
| May 03, 2024 | $2.08 |
| May 06, 2024 | $2.12 |
| May 07, 2024 | $2.37 |
| May 08, 2024 | $2.04 |
| May 09, 2024 | $2.09 |
| May 10, 2024 | $2.19 |
| May 13, 2024 | $2.23 |
| 4 days before | 16.18% |
| 4 days after | -5.91% |
| On release day | -13.92% |
| Change in period | 9.31% |
Q2 2024
Beat
| Release date | Aug 12, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $1.84 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.0500 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| Aug 06, 2024 | $2.01 |
| Aug 07, 2024 | $1.96 |
| Aug 08, 2024 | $2.03 |
| Aug 09, 2024 | $2.02 |
| Aug 12, 2024 | $1.84 |
| Aug 13, 2024 | $1.80 |
| Aug 14, 2024 | $1.86 |
| Aug 15, 2024 | $1.97 |
| Aug 16, 2024 | $1.96 |
| 4 days before | -8.46% |
| 4 days after | 6.52% |
| On release day | -2.17% |
| Change in period | -2.49% |
Q3 2024
Missed
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $2.11 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.150 |
| EPS surprise | -7.14% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $2.03 |
| Nov 04, 2024 | $2.00 |
| Nov 05, 2024 | $2.12 |
| Nov 06, 2024 | $2.21 |
| Nov 07, 2024 | $2.11 |
| Nov 08, 2024 | $2.28 |
| Nov 11, 2024 | $2.52 |
| Nov 12, 2024 | $2.43 |
| Nov 13, 2024 | $2.23 |
| 4 days before | 3.94% |
| 4 days after | 5.69% |
| On release day | 8.06% |
| Change in period | 9.85% |
Q4 2024
Beat
| Release date | Mar 04, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $1.77 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.100 |
| EPS surprise | 28.57% |
| Date | Price |
|---|---|
| Feb 26, 2025 | $1.65 |
| Feb 27, 2025 | $1.66 |
| Feb 28, 2025 | $1.70 |
| Mar 03, 2025 | $1.58 |
| Mar 04, 2025 | $1.77 |
| Mar 05, 2025 | $1.65 |
| Mar 06, 2025 | $1.59 |
| Mar 07, 2025 | $1.69 |
| Mar 10, 2025 | $1.58 |
| 4 days before | 7.27% |
| 4 days after | -10.73% |
| On release day | -6.78% |
| Change in period | -4.24% |
Esperion Therapeutics Earnings Call Transcript Summary of Q4 2024
Prescription Growth
The company achieved a 12% sequential quarterly growth in Total Retail Prescription Equivalents (TRPEs) in Q4.
Collaboration Revenue
Increased by 227% to $37.6 million, attributed to strong performance from their partner in Europe and a milestone payment from Otsuka.
Cost Management
Reduced R&D and SG&A expenses, leading to improved profitability metrics.
Product Developments
- FDA Approval: The company received expanded labels for NEXLETOL and NEXLIZET, which now provide FDA-approved options for LDL cholesterol reduction and cardiovascular risk management.
- Market Access Expansion: Coverage expanded to over 173 million lives in the U.S., with the products being included in the U.S. Department of Defense formulary.
- Increasing Prescriber Base: The prescriber base has grown by 10%, indicating potential for future growth.
- Triple Combination Products: Plans to develop triple combination therapy involving bempedoic acid with statins to further enhance LDL-C lowering and support more treatment options for statin-intolerant patients.
International Growth
- Global Partnerships: Successful collaborations with Otsuka in Japan and DSE in Europe, with expectations of significant revenue contributions from these regions.
- New Licensing Agreements: The company is entering additional markets, including Australia, New Zealand, and Israel to further expand their international footprint.
Strategic Focus Areas
- Three Pillars of Growth: The strategy revolves around increasing revenue, achieving operating profitability, and expanding their portfolio through pipeline advancements and in-licensing opportunities.
- Research and Development: Commitment to R&D continues, with plans for an R&D Day on April 24, 2025, to unveil new candidates and development timelines.
- Market Awareness Efforts: Ongoing initiatives to raise awareness about statin intolerance and the efficacy of bempedoic acid products among healthcare providers and patients.
Operational Highlights
- Pricing and Gross-to-Net Impact: Anticipated normalization of gross-to-net rates in 2025, which should align quarterly revenue growth more closely with TRPE growth rates.
- Innovative Sales Strategies: The company is actively engaging consumers to stimulate demand for their products, leveraging digital assets to increase awareness and prescription rates.
Takeaway for Investors
Esperion Therapeutics is positioned for significant growth in 2025, supported by strong revenue momentum, international expansion, and innovative product development strategies. Their concentration on increasing awareness and establishing effective collaborations may provide a robust foundation for future profitability and market share growth. Investors should watch for upcoming milestones, particularly in international markets and developments surrounding combination therapies.
Esperion Therapeutics Earnings History
Earnings Calendar
FAQ
When is the earnings report for ESPR?
Esperion Therapeutics (ESPR) has scheduled its earnings report for May 06, 2025 before the markets open.
What is the ESPR price-to-earnings (P/E) ratio?
ESPR P/E ratio as of Mar 17, 2025 (TTM) is -5.69.
What is the ESPR EPS forecast?
The forecasted EPS (Earnings Per Share) for Esperion Therapeutics (ESPR) for the first fiscal quarter 2025 is -$0.180.
What are Esperion Therapeutics's retained earnings?
On its balance sheet, Esperion Therapeutics reported retained earnings of $69.11 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
